11
1
2
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10923 | CYP17-IN-1 | P450 | |
CYP17-IN-1 is an effective oral inhibitor of CYP17 that can inhibit CYP17 in rats and humans with IC50 of 15.8 and 20.1 nM. | |||
T13312L | Seviteronel | VT-464 | P450 , Androgen Receptor |
Seviteronel (VT-464) is a novel CYP17 cleavage enzyme inhibitor and androgen receptor antagonist for the study of breast and prostate cancer. | |||
T6216 | Abiraterone | CB-7598 | P450 |
Abiraterone (CB-7598) (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM). | |||
T6509 | Galeterone | VN-124-1,TOK-001,VN/124-1,VN 124 | P450 , Androgen Receptor |
Galeterone (VN 124) is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an a... | |||
T30161 | EN3356 | AS N001,ASN-001 | P450 |
EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and ant... | |||
T6215 | Abiraterone Acetate | Zytiga,CB7630 | P450 |
Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. | |||
T13313 | Seviteronel racemate | VT-464 (racemate) | Others |
Seviteronel racemate is the racemate form of Seviteronel and is a potent inhibitor of CYP17 lyase. | |||
T63434 | Abiraterone decanoate | ||
Abiraterone decanoate is a prodrug of Abiraterone that provides controlled release and long-lasting CYP17 inhibition of Abiraterone using intramuscular (IM) delivery. | |||
T71102 | CFG920 | ||
CFG920 is a CYP17 inhibitor, is also an orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration,... | |||
T13312 | Seviteronel R enantiomer | VT-464 (R enantiomer) | Others |
Seviteronel R enantiomer is the R enantiomer of Seviteronel and is a potent inhibitor of CYP17 lyase (IC50: 69 nM for h-Lyase). | |||
T6051 | Orteronel | TAK-700,(S)-Orteronel | P450 |
Orteronel ((S)-Orteronel)(TAK-700) was selected as a candidate for clinical evaluation. orteronel (TAK-700) is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T0603 | Phthalic acid mono-2-ethylhexyl ester | Phthalic Acid Monooctyl Ester | P450 , Endogenous Metabolite |
Phthalic acid mono-2-ethylhexyl ester (Phthalic Acid Monooctyl Ester is a major bioactive metabolite of diethylhexyl phthalate (DEHP), which inhibits the 17, 20 lyase activity of CYP17. Cyp17a1 gene is a specific target ... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-02139 | CYP17A1 Protein, Human, Recombinant (GST) | Human | E. coli |
A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen sy... | |||
TMPH-02143 | NR5A1 Protein, Human, Recombinant (His) | Human | E. coli |
Transcriptional activator. Essential for sexual differentiation and formation of the primary steroidogenic tissues. Binds to the Ad4 site found in the promoter region of steroidogenic P450 genes such as CYP11A, CYP11B an... |